Farxiga Diabetes Drug Design Flaw Claim Out, Warning Claim In

Federal law doesn’t block a Mississippi woman’s claim that the diabetes drug Farxiga should have been designed properly before approval, but the claim nonetheless warrants dismissal, a federal court in Mississippi said (Young v. Bristol-Myers Squibb Co., 2017 BL 54859, N.D. Miss., No. 16-00108, 2/22/17).

Kamilah Young sued manufacturers Bristol-Myers Squibb Co. and AstraZeneca Pharmaceuticals LP, alleging Farxiga caused kidney failure.

The U.S. Judicial Panel on Multidistrict Litigation is set March 30 to consider whether to combine federal Farxiga personal injury suits, including Young’s, into one proceeding before a single judge.

Here, Bristol-Myers and AstraZeneca argued Young’s design ...